Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting

Abstract Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venetoclax (VEN) with hypomethylating agents has been established as the standard treatment for elderly or med...

Full description

Bibliographic Details
Main Authors: Xubo Gong, Xin He, Lin Wang, Teng Yu, Weiwei Liu, Huiying Xu, Lan Jin, Xiang Li, Bin Zhang, Zhihua Tao, Wenbin Qian
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Experimental Hematology & Oncology
Subjects:
Venetoclax
Acute myeloid leukemia
Hypomethylating agents
Online Access:https://doi.org/10.1186/s40164-024-00486-7

Internet

https://doi.org/10.1186/s40164-024-00486-7

Similar Items